1 MILLION-FOLD GREATER EXPANSION

What happens when aging cells are given a “younger” microenvironment?

A recent study published in Aging Cell provides compelling evidence that the extracellular matrix surrounding a cell can have a profound impact on its behavior.

Researchers at UT Health San Antonio investigated aging adipose-derived mesenchymal stem cells (AD-MSCs) cultured on CELLvo™ Matrix Plus from StemBioSys compared with traditional tissue culture plastic.

The results were striking.

🔬 CELLvo™ Matrix Plus significantly improved the expansion and quality of aging MSCs.

Compared with cells maintained on traditional tissue culture plastic, MSCs cultured on CELLvo™ Matrix Plus demonstrated:

• Faster and sustained proliferation — doubling time was approximately 35 hours on CELLvo™ Matrix Plus versus approximately 92 hours on tissue culture plastic.

• Dramatically greater cell expansion — after seven passages, the number of cells maintained on CELLvo™ Matrix Plus was approximately 1 million-fold greater than those maintained on tissue culture plastic.

• Reduced markers of cellular senescence — including reductions in reactive oxygen species and β-galactosidase activity.

• Preservation of telomere length, supporting maintenance of cellular quality during extended expansion.

• Higher expression of SSEA-4, an early-stage stem/progenitor cell marker.

• Enhanced differentiation capacity, including improved colony formation and cartilage, adipogenic, and osteogenic differentiation outcomes.

The study also identified increased CD74 expression and activation of the PI3K pathway in cells maintained on CELLvo™ Matrix Plus , providing insight into a potential mechanism by which a native young extracellular environment may support cell survival and suppress senescence.

Why does this matter?

As researchers work with increasingly aged or biologically stressed cells, the culture environment itself may be an important variable in maintaining cell quality and function.

Rather than simply providing a surface for cells to attach, a physiologically relevant extracellular matrix can provide the biochemical and structural cues that cells experience within their native microenvironment.

CELLvo™ Matrix Plus —also referred to as ECM Plus—was developed with this principle in mind.

This study adds to the growing body of evidence that the right extracellular environment can make a meaningful difference in how cells behave in vitro.

We are proud to see StemBioSys technology contributing to research exploring new approaches to cellular aging, regenerative medicine, and cell-based therapies.

📄 Read the full publication:
https://doi.org/10.1111/acel.70165

#StemBioSys #ECMPlus #CELLvoMatrixPlus #ExtracellularMatrix #MesenchymalStemCells #MSC #CellCulture #StemCellResearch #RegenerativeMedicine #CellularAging #CellTherapy #AgingResearch

CELLvo™ Matrix Plus

StemBioSys Awarded an SBIR Grant to Advance Islet Transportation using ECM

StemBioSys Awarded an SBIR Grant to Advance Islet Transportation using ECM

Pancreatic islet transplantation is a surgical procedure used in the treatment of patients with type 1 (or latter-stage type 2) diabetes. It involves transplanting islets of Langerhans (hormone-producing pancreatic cell clusters) from a donor pancreas to the patient’s pancreas, with the goal of regulating blood glucose levels and minimizing hypoglycemia and diabetic complications.

HepatoMatrix: Maturing Hepatocytes For in Vitro Hepatotoxicity Testing

HepatoMatrix: Maturing Hepatocytes For in Vitro Hepatotoxicity Testing

The liver is one of the more complex organs in the human body, and performs many essential functions, including digestion and drug metabolism. In addition to being complex, the liver is also extremely adaptable and can regenerate itself if damaged. Hepatocytes account for about 60% of the cells within the liver, and are responsible for most of its metabolic activity, detoxification, protein secretion and bile production.

CCN1 and the Bone Marrow Mesenchymal Stem Cell Niche

CCN1 and the Bone Marrow Mesenchymal Stem Cell Niche

Matrix Biology’s August 2022 edition includes a report entitled “Matrix-bound Cyr61/CCN1 is required to retain the properties of the bone marrow mesenchymal stem cell niche but is depleted with aging”. The report is written by StemBioSys scientific advisor Milos Marinkovic, Ph.D., Assistant Professor in the Department of Comprehensive Dentistry at University of Texas Health at San Antonio. It is based on studies conducted with a team of scientists including StemBioSys CTO Travis Block, Ph.D. and StemBioSys founder and scientific advisor Xiao-Dong Chen, M.D., Ph.D., Professor in the Department of Comprehensive Dentistry at University of Texas Health at San Antonio.

NeuroMatrix™ and Challenges in Neuronal Culture

NeuroMatrix™ and Challenges in Neuronal Culture

For scientists studying neurodegenerative disease, investigating new neuroactive drugs, or looking to avoid neurotoxicity in new pharmaceuticals (neurotoxicity is the #1 cause of clinical stage drug attrition), the use of neuronal cell culture shows great promise for modeling aspects of the most complex organ in the body, so that we may gain new insights to advance basic and translational research.

Phasing Out Animal Testing

Phasing Out Animal Testing

The FDA Modernization Act, which was unanimously passed by the Senate in September 2022, seeks to diversify the methods by which drug companies can test their products for safety and efficacy before they are marketed to the public. The passing of this bill represents the culmination of years of research and collaboration between scientists, drug company representatives and various members of the government. 

Cartilage Tissue Engineering: a New Frontier in Knee Rehabilitation

Cartilage Tissue Engineering: a New Frontier in Knee Rehabilitation

Several years ago, The U.S. Food and Drug Administration (FDA) approved a product called MACI® for the repair of knee cartilage defects in adult patients. MACI, an acronym for matrix-induced autologous chondrocyte implantation, is an advanced cell therapy developed and marketed by American biopharmaceutical company Vericel Corporation; it utilizes the groundbreaking technique of cartilage tissue engineering to address knee damage resulting from injury, overuse and surrounding muscle weakness.